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bstract
Background. Previous studies have demonstrated that serum anti-actin antibodies are a reliable marker of intestinal damage severity in
oeliac disease.
Aims. To validate in a multicentre study the clinical usefulness of serum IgA anti-actin antibody ELISA and its possible use in monitoring
ntestinal mucosa lesions during gluten-free diet.
Patients and methods. Four centres recruited 205 newly diagnosed coeliac disease patients with villous atrophy, 80 healthy controls
nd 81 “disease” controls. Twelve coeliac disease patients on gluten-free diet but with persistent symptoms underwent serum IgA anti-actin
ntibody assay and intestinal histology evaluation. IgA anti-actin antibody ELISA was performed with a commercial kit. All coeliac disease
atients underwent intestinal histology study.
Results. IgA anti-actin antibodies showed a sensitivity of 80% and a specificity of 85% in the diagnosis of coeliac disease patients with
illous atrophy. The area under the receiving operator curve for anti-actin antibodies was 0.873 [95% C.I. 0.805–0.899]. Serum anti-actin
ntibodies values were significantly higher in coeliac disease patients than in healthy or “disease” controls (P < 0.0001). Serum anti-actin
ntibodies were positive in 41 of the 60 coeliac disease patients with mild intestinal histology lesions (69%) and in 123 of the 145 with severe
esions (85.3%) (P < 0.05). There was a significant inverse correlation between anti-actin antibody values and the villi/crypts ratio (r = −0.423;
< 0.0001). In the 12 coeliac disease patients on gluten-free diet who underwent re-evaluation as they were persistently symptomatic, intestinal
istology showed three cases with persistent villous atrophy: all of these were positive for serum anti-actin antibodies ELISA, whereas both
erum anti-tTG and EmAs were negative. The other nine patients showed normal intestinal villi and were negative for serum anti-actin
ntibodies.
Conclusions. Anti-actin antibodies are a reliable marker of severe intestinal mucosa damage in coeliac disease patients and a simple ELISA
echnique offers an accurate method for their determination. These antibodies seem to be a very reliable marker of persistent intestinal damage
n coeliac disease patients.
2007 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
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oi:10.1016/j.dld.2007.06.004. IntroductionCoeliac disease (CD) is an immune-mediated enteropa-
hy triggered by gluten ingestion in genetically predisposed
ndividuals. It is nowadays evident that CD is one of the
vier Ltd. All rights reserved.
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ost common life-long diseases, with a frequency around
:100–1:200 in the general population [1–3]. The enor-
ous increase in CD diagnoses in recent decades is in large
art due to the availability of serum tests with excellent
iagnostic accuracy, such the anti-endomysium and anti-
ransglutaminase assays [4–6]. However, these assays do not
eflect the severity of the intestinal mucosa damage [7,8].
n this respect, the immunofluorescence (IF) assay of IgA
nti-actin antibodies (AAA) has been suggested as a useful
ethod [9,10] and we recently described an ELISA which
emonstrated to be an accurate assay for their determination
11].
This multicentre study was designed to evaluate the clini-
al usefulness of serum IgA AAA ELISA in a greater number
f CD patients and its possible use in monitoring intestinal
ucosa lesions during gluten-free diet.
. Patients and methods
CD patients were recruited in four centres (three for adults
nd one for paediatric CD) between January and December
004. A total of 205 CD patients were enrolled. IgA AAAs
ere assayed on the stored sera of 155 adult CD patients
50 M, 105 F, median age 24 years, range 18–76 years)
nd 50 paediatric CD patients (22 M, 28 F, median age 16
onths, range 1–14 years). The sera were collected at CD
iagnosis, after overnight fasting, and frozen at −80 ◦C for a
ean time of 14 months (range 12–24 months) before AAA
etermination. A previous study had shown that preserva-
ion at −80 ◦C did not significantly alter results (inter-assay
oefficient of variation was 8.5%) [11]. The CD clinical
resentation was typical (malabsorption syndrome) in 105
atients, atypical (absence of intestinal symptoms) in 85 and
ilent in 15 (patients identified through screening programs)
12].
In all patients, CD diagnosis was based on serum EmA
nd anti-tTG positivity associated with evidence of intesti-
al villi damage (villous height/crypt depth ratio <3), and in
ll cases on a subsequent gluten-free diet clinical symptoms
isappeared and EmA and anti-tTGs became negative. As
healthy” controls we enrolled 80 subjects (54 adults eval-
ated for suspected hypercholesterolaemia: 25 M and 29 F,
edian age 29 years, range 18–59 years; and 26 children
ith recurrent pharyngo-tonsilitis, 10 M and 16 F, median
ge 2 years, range 1–11 years). None of the controls had
ymptoms or laboratory signs suggesting CD diagnosis and
ll were negative for EmA and anti-tTG assays. A further 81
dult subjects with autoimmune or gastrointestinal diseases
ther than CD were enrolled as “disease” controls for IgA
AA assay: type 1 autoimmune hepatitis (4 cases), systemic
upus erythematosus (5 cases), Sjogren’s disease (4 cases),
rimitive biliary cirrhosis (2 case), active Crohn’s disease
40 cases), active ulcerative colitis (20 cases), multiple food
ntolerance (6 cases). All these patients were negative for
mA and anti-tTG assays.
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Finally, 12 CD patients (4 M, 8 F, median age 25 years,
ange 18–49 years) on gluten-free diet for a median time of 20
onths (range 14–48 months), but with persistent symptoms,
nderwent serum IgA anti-tTG and AAA assays and gastro-
uodenoscopy with multiple duodenal biopsy.
Informed consent was obtained from the adult patients
nvolved in the study and from the parents of the paediatric
atients. The study was approved by the Ethics Committee
f the University Hospital of Palermo.
.1. Serology for CD diagnosis and IgA AAA indirect
mmunoﬂuorescence assay
IgA EmAs and anti-tTGs were assayed with commercial
its as previously described [6].
IgA AAA enzyme immunoassay (ELISA) was performed
n the laboratory of the “Buccheri La Ferla Hospital” of
alermo, using a commercial kit for anti-actin IgG deter-
ination (F-Actin Smooth Muscle, INOVA, San Diego,
alifornia, US, ref. 708785) and an anti-serum anti-human
gA conjugate (INOVA, ref. 508549). A 1:101 dilution of
erum sample from each patient was prepared and 100L of
he diluted serum was added to the wells and incubated for
0 min at room temperature. The wells were washed three
imes with buffer. Hundred microlitres of the IgA conjugate
as added to each well and the plates were incubated for
0 min and washed again. Hundred microlitres of TMB chro-
ogen was added to each well and incubated in the dark for
0 min at room temperature. Stopped reactions were read at
50 nm and 620 nm. The control wells (no serum) introduced
n each plate showed an absorbance of <0.025. AAA results
ere expressed as arbitrary units (AU) in comparison with
aboratory standards. The reference curve was obtained by
ooling 20 sera from patients highly positive for AAAs (pos-
tive controls), evaluated by IF, whereas 20 sera negative for
AAs from healthy controls were mixed and used as nega-
ive controls. The threshold normal value was established at
.8 AU, which was equal to the mean value +3 S.D. obtained
n healthy subjects.
The examiners were unaware of the diagnoses and the
ther laboratory test results. Intra- and inter-assay coefficients
f variation (CV) were calculated on 20 samples. The method
howed a high reproducibility: intra-assay CV 3.4% and inter-
ssay CV 8.8%.
.2. Intestinal histology
At least three biopsy specimens of the second part of the
uodenum were obtained from each CD patient and orien-
ated as previously described [6]. Specimens were embedded
n paraffin. Slides were stained with haematoxylin and
osin and graded by conventional histology according to
orazza and Villanacci [13] as normal villi and crypts (Grade
), partial villous atrophy (Grade B), total villous atrophy
Grade C). Furthermore, the ratio between villous height
nd crypt depth was calculated for each sample. Histology
8 nd Liver Disease 39 (2007) 818–823
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as described by an examiner unaware of the laboratory test
esults.
. Statistical analysis
We followed the STARD checklist for studies on the diag-
ostic accuracy of tests [14].
The percentage (and 95% C.I.) of IgA AAA positive
esults was calculated in the CD patients, controls and
n the CD patients with partial or total villous atrophy.
he chi-square test was used for frequency analysis. The
ann–Whitney U-test was used to compare the serum IgA
AA ELISA results in CD patients and in the control
ubjects. Spearman’s r correlation coefficient was used to
valuate the association of serum AAA values with severity
f intestinal mucosa damage (villi/crypts ratio). In addition,
eceiving operator curves (ROCs) were plotted to show the
iscriminative ability of the tests. The model plots sensitivity
the proportion of CD patients attributed by the test to the CD
roup) versus 1-specificity (the proportion of control patients
ttributed by the tests to the CD group). The areas under the
OC curves and their 95% confidence intervals were also
alculated using the non-parametric method described by
anley and McNeil [15], developed as a statistical program.
. Results
Fig. 1 shows the individual IgA AAA values in the study
roups. Serum IgA AAA evaluated by ELISA were posi-
ive in 164 of the 205 (80%, 95% C.I. 72.2–87.8) untreated
D patients. Twenty-nine adults and 12 children with CD
ere negative. Among the 80 healthy controls, 1 subject
as positive for serum AAAs, whereas in the group of
disease controls” 23 of the 81 patients were positive. On
he basis of the above results, AAAs showed a sensitivity
f 80% (95% C.I. 73–88.6%) and, considering as a single
Fig. 1. Individual serum IgA AAA values in the three studied groups.
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Eig. 2. Receiving operator curve (ROC) for serum IgA anti-actin performed
fter cumulative analysis of the data from CD patients and the whole group
f control (healthy plus “disease” controls).
roup both the healthy and “disease” controls, a specificity
f 85% (95% C.I. 76–91%). The specificity went down to
2% when exclusively the “disease controls” were consid-
red. After performing a cumulative analysis of the data from
he patients and healthy plus “disease” controls, we plotted
he ROC curve for AAAs: the area under curve was 0.873
95% C.I. 0.805–0.899] (Fig. 2). However, when consider-
ng in the cumulative analysis the data from the CD patients
nd from the patients with non-CD autoimmune diseases or
nteropathy (“disease” controls), the area under the curve was
ignificantly lower: 0.836 (95% C.I. 0.778–0.885; P = 0.05).
Serum AAAs values were significantly higher in the CD
atients (median value 17.7 AU, range 3–111) than in healthy
ontrols (median value 2.4 AU, range 1.1–23.3) (z = 13.34,
< 0.0001) and “disease” controls (median value 3.8, range
.1–21.6 AU) (z = 9.32, P < 0.0001).
Intestinal histology of the CD patients revealed that 60
ad partial villous atrophy (Grade B) and 145 had total villous
trophy (Grade C). Serum AAAs were positive in 41 of the 60
D patients with Grade B lesions (69%, 95% C.I. 59.9–78%)
nd in 123 of the 145 with Grade C lesions (85.3%, 95% C.I.
8.4–92.4) (P < 0.01). Table 1 resumed the percentage of pos-
tive IgA AAA in the study groups. Furthermore, there was a
ignificant inverse correlation between AAA values and the
illi/crypts ratio in each patient with r = −0.423 (P < 0.0001).
nti-tTG values and EmA titer showed a significant but lower
nverse correlation with severity of intestinal mucosa damage
for anti-tTGs: r = −0.381; for EmAs: r = −0.328).
Table 2 summarizes the clinical characteristics, intesti-
al histology findings and serum assay results of the 12
D patients on gluten-free diet who underwent re-evaluation
s they were persistently symptomatic. Intestinal histology
howed three cases with persistent villous atrophy (total
n one patient and partial in two): all these were positive
or serum AAAs ELISA, whereas both serum anti-tTG and
mAs were negative. These three patients declared they
A. Carroccio et al. / Digestive and Liver Disease 39 (2007) 818–823 821
Table 1
Number of cases and percentages of positive IgA anti-actin antibodies in the different study groups: coeliac patients (according to the grade of intestinal
damage), healthy controls and “disease” controls
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(D with partial villi atrophy CD with total villi atroph
1/60 (69%) 123/145 (85.3%)
ere strictly adhering to the gluten-free diet. The other nine
atients showed normal intestinal villi, although most of them
howed an elevated number of intra-epithelial lymphocytes.
ll these nine cases had negative serum AAAs, anti-tTG and
mAs.
. Discussion
The best serological approach to diagnose CD is based
n the EmA and anti-tTG assays, which have a very high
iagnostic accuracy [4–6,16,17]. However, these serological
ests do not correlate with histopathological features [8,18]
nd only recently another test – the AAA assay – has been
roposed as a marker of the severity of intestinal mucosa
amage in CD [9,10].
In the present multicentre study we assayed IgA AAAs
ith an ELISA which had demonstrated to be an accurate
ethod for AAA determination [11]. Our results showed that
n a group of CD patients, all positive for EmA and anti-tTG
ssays, serum IgA AAAs had 80% sensitivity and 82% speci-
city, thus we confirmed that they are less accurate than the
raditional assays in CD diagnosis. Furthermore, it must be
nderlined that all the CD patients included in this study
ad various degree of villi atrophy and, as regards the test
pecificity, it is known that serum AAAs can be detected
n patients with autoimmune diseases and in healthy sub-
ects [19]. However, one study reported cases of CD patients
egative for serum EmA and positive for IgA AAAs and sug-
ested that this combination, EmA−/AAA+, could indicate
omplicated CD cases [20]. Others suggested that serum IgA
AA assay associated with other antibodies assays could
c
f
F
able 2
linical characteristics, intestinal histology findings and serum assay results of the
atient GFD duration Symptoms causing the re-evaluation Intest
1 20 Anaemia, diffuse abdominal pain Grade
2 48 Dyspepsia Grade
3 20 Dyspepsia, anaemia Grade
4 14 Weight loss Grade
5 19 Anaemia Grade
6 17 Dyspepsia Grade
7 15 Diarrhoea, anaemia Grade
8 18 Diarrhoea, anaemia Grade
9 30 Dyspepsia Grade
0 32 Dyspepsia Grade
1 23 Anaemia Grade
2 24 Dyspepsia, anaemia Grade
otes: (1) GFD: gluten-free diet; anti-tTG: anti-transglutaminase; EmA: anti-endom
3) Severity of the intestinal histology damage is given as follows: normal villi and
Grade C) (see reference [13]).Healthy controls “Disease” controls
1/80 (1.3%) 23/81 (28%)
ubstitute the EmA assay [21]. Our results, however, are
n agreement with those reported by other Italian studies
hich showed that IgA AAA assay cannot replace EmA
nd anti-tTG in the diagnostic algorithm of CD [10,22].
urthermore, we confirmed that serum AAA positivity is
ndicative of more severe intestinal histology damage. In
act, serum AAAs were found more frequently positive in
he CD patients with total villous atrophy (85%) than in CD
atients with partial villous atrophy (69%) and there was a
ignificant inverse correlation between IgA AAA values and
he villi/crypts ratio (P < 0.0001) with a correlation coeffi-
ient value higher than those shown by anti-tTG and EmA
alues.
Another important finding was IgA AAA positivity in
he CD patients on gluten-free diet who showed persistent
ymptoms associated with intestinal mucosa damage. Inter-
stingly, these patients declared they were adhering to the
luten-free diet and both anti-tTG and EmA assays were neg-
tive. Although we cannot explain the causes of the persistent
istology damage at 14–20 months after commencement of
he gluten-free diet, it is relevant that only IgA AAA assay
orrectly identified these patients and this assay was nega-
ive in all the other CD patients with persistent symptoms but
ontemporary evidence of complete intestinal villi recovery.
his seems to confirm that in CD, serum IgA AAAs can be
onsidered a direct expression of severity of intestinal dam-
ge and monitoring them could be useful to detect intestinal
istology recovery or damage persistence.IgA AAA ELISA, re-evaluated in the context of a multi-
entre study, confirmed to be a simple and reliable method. In
act, it was able to detect the antibodies which react against
-actin, the polymerized form of actin which in vitro study
12 CD patients on gluten-free diet who underwent re-evaluation
inal histology Serum anti-tTG Serum EmA Serum AAA
B Negative Absent Positive
A Negative Absent Negative
A Negative Absent Negative
C Negative Absent Positive
A Negative Absent Negative
A Negative Absent Negative
B Negative Absent Positive
A Negative Absent Negative
A Negative Absent Negative
A Negative Absent Negative
A Negative Absent Negative
A Negative Absent Negative
ysium; AAA: anti-actin. (2) Duration of the GFD diet is given in months.
crypts (Grade A), partial villous atrophy (Grade B), total villous atrophy
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23] has shown to be induced in the intestinal epithelial cells
f CD patients minutes after gliadin incubation.
In conclusion, we confirmed that IgA AAAs are a reliable
arker of severe intestinal mucosa damage in CD patients
nd that a simple ELISA technique offers an accurate method
or their determination. These antibodies seem to be a very
eliable marker of persistent intestinal damage in CD patients.
Practice points
• IgA AAAs have been shown in a high per-
centage of CD patients with severe intestinal
histology damage.
• A simple AAA ELISA showed high sensi-
tivity in CD patients, comparable with that
reported using the “classical” immunoﬂuo-
rescence technique.
• Using AAA ELISA the frequency of positive
assays correlates with the severity of the
intestinal damage.
• IgA AAA seems to be a reliable marker of
persistent intestinal mucosa damage in CD
patients on gluten-free diet.
Research agenda
• Prospective studies on a greater number of
CD patients on gluten-free are needed to
better understand the usefulness of AAA
assay in monitoring the state of the intestinal
mucosa.
• Further studies would be performed to eval-
uate whether the association of AAA assay
with EmA and/or anti-tTG improves the diag-
nostic accuracy of serologic tests in CD
diagnosis.
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